22,878 Shares in Arcutis Biotherapeutics, Inc. $ARQT Purchased by Virtus Advisers LLC

Virtus Advisers LLC bought a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,878 shares of the company’s stock, valued at approximately $605,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Aberdeen Group plc grew its position in Arcutis Biotherapeutics by 9.7% in the third quarter. Aberdeen Group plc now owns 1,204,900 shares of the company’s stock valued at $31,846,000 after acquiring an additional 106,489 shares during the period. Allworth Financial LP lifted its holdings in shares of Arcutis Biotherapeutics by 158.2% during the third quarter. Allworth Financial LP now owns 2,089 shares of the company’s stock valued at $55,000 after acquiring an additional 1,280 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Arcutis Biotherapeutics by 244.6% during the third quarter. Russell Investments Group Ltd. now owns 116,225 shares of the company’s stock valued at $3,072,000 after acquiring an additional 82,500 shares during the period. Fifth Third Bancorp boosted its stake in shares of Arcutis Biotherapeutics by 6,472.7% in the 3rd quarter. Fifth Third Bancorp now owns 23,136 shares of the company’s stock valued at $611,000 after purchasing an additional 22,784 shares in the last quarter. Finally, Maryland State Retirement & Pension System bought a new stake in shares of Arcutis Biotherapeutics in the 3rd quarter worth about $674,000.

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 4,377 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $139,451.22. Following the completion of the sale, the insider owned 712,826 shares in the company, valued at approximately $22,710,636.36. This trade represents a 0.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard G. Welgus sold 4,728 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $26.93, for a total transaction of $127,325.04. Following the completion of the transaction, the director directly owned 35,207 shares of the company’s stock, valued at approximately $948,124.51. This represents a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 104,202 shares of company stock worth $3,034,393 over the last quarter. Corporate insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock opened at $28.26 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 2.92. The firm has a market cap of $3.57 billion, a P/E ratio of 134.58 and a beta of 1.66. The business’s fifty day moving average is $27.54 and its two-hundred day moving average is $25.40. Arcutis Biotherapeutics, Inc. has a 52 week low of $19.30 and a 52 week high of $34.80.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%. The business had revenue of $143.92 million for the quarter, compared to the consensus estimate of $142.59 million. Equities research analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $39.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 29th. TD Cowen raised their price objective on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Needham & Company LLC set a $40.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday, November 5th. Finally, Wall Street Zen cut shares of Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.75.

Check Out Our Latest Report on Arcutis Biotherapeutics

About Arcutis Biotherapeutics

(Free Report)

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.

Further Reading

Want to see what other hedge funds are holding ARQT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report).

Institutional Ownership by Quarter for Arcutis Biotherapeutics (NASDAQ:ARQT)

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.